Tag: Herpes Zoster (Shingles)
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
In adults aged 50 years or older, two-dose recombinant zoster vaccine linked to reduced risk for HZO, acute myocardial infarction, stroke
FDA Approves Prefilled Syringe Presentation for Shingles Vaccine
Prefilled syringe eliminates the need to reconstitute separate vials prior to administration and simplifies the vaccine process
Live Zoster Vaccination Linked to Lower Risk for Cardiovascular Events
In a recent study, protective association lasted for up to eight years, with greatest reduction seen at two to three years postvaccination
Zoster Vaccine Has Dementia-Preventing or Delaying Effect
Receipt of zoster vaccine reduces probability of new dementia diagnosis over seven-year period by 3.5 percentage points
AAO: One Year of Valacyclovir Beneficial for Herpes Zoster Ophthalmicus
Significant treatment benefits seen at 18 months; in addition, risk for experiencing subsequent end points lower with valacyclovir
Herpes Zoster Linked to Increased Long-Term Risk for Cognitive Decline
HZ linked to increased risk for 3-unit increment in subjective cognitive decline score in the long term in Nurses' Health Study cohort
Two Doses of Recombinant Zoster Vaccine Highly Effective
Vaccine effectiveness wanes after one dose but remains relatively unchanged over four years after two doses
Effectiveness of Live Zoster Vaccine Wanes Over Time
Vaccine effectiveness highest in first year after vaccination and decreases considerably over time
Routine Vaccines Can Cut Risk for Later Alzheimer Disease
Findings seen for tetanus and diphtheria, shingles, and pneumococcus vaccines
Herpes Zoster Linked to Increased Risk for Cardiovascular Disease Events
Long-term risks for stroke and coronary heart disease increased for individuals with history of herpes zoster versus those with no history of herpes zoster
